Brainstorm Cell Therapeutics, Inc. BCLI

NAS: BCLI | ISIN: US10501E2019   3/05/2024
0,380 USD (-4,59%)
(-4,59%)   3/05/2024

17 april 2024 · BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn · Persbericht

11 april 2024 · BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule · Persbericht

10 april 2024 · BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS · Persbericht

9 april 2024 · BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS · Persbericht

8 april 2024 · BrainStorm Cell Therapeutics to Provide Update on NurOwn Program · Persbericht

1 april 2024 · BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update · Persbericht

27 februari 2024 · BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference · Persbericht

23 februari 2024 · BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS · Persbericht

13 februari 2024 · BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum · Persbericht

28 december 2023 · BRAINSTORM INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their Options · Persbericht

26 december 2023 · BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments · Persbericht

21 december 2023 · BRAINSTORM INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their Options · Persbericht

20 december 2023 · BrainStorm Issues 2023 Letter to Shareholders · Persbericht

15 december 2023 · BCLI Investors Have Opportunity to Lead Brainstorm Cell Therapeutics Inc. Securities Fraud Lawsuit · Persbericht

7 december 2023 · BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS · Persbericht

5 december 2023 · BRAINSTORM SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their Options · Persbericht

1 december 2023 · BCLI Investors Have Opportunity to Lead Brainstorm Cell Therapeutics Inc. Securities Fraud Lawsuit · Persbericht

13 november 2023 · BRAINSTORM INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options · Persbericht

13 november 2023 · SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Brainstorm Cell Investors of a Lead Plaintiff Deadline of January 2, 2024 · Persbericht

11 november 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI · Persbericht

Mijn selecties